On Wednesday, Vertex Pharmaceuticals VRTX will release its latest earnings report. Decipher the announcement with Benzinga's help.
Earnings and Revenue
Analysts covering Vertex Pharmaceuticals modeled for quarterly EPS of 74 cents on revenue of $682.24 million.
The Wall Street estimate would represent a 89.74 percent increase in the company's earnings. Sales would be up 31.98 percent from the same quarter last year. The company's reported EPS has stacked up against analyst estimates in the past like this:
Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
EPS Estimate | 0.62 | 0.53 | 0.3 | 0.35 |
EPS Actual | 0.76 | 0.61 | 0.53 | 0.39 |
Stock Performance
Over the last 52-week period, shares are up 7.18 percent. Given that these returns are generally positive, long-term shareholders can be satisfied going into this earnings release.
Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. The popular rating by analysts on Vertex Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.